LFMD logo

LifeMD, Inc. Stock Price

NasdaqGM:LFMD Community·US$235.5m Market Cap
  • 4 Narratives written by author
  • 1 Comments on narratives written by author
  • 117 Fair Values set on narratives written by author

LFMD Share Price Performance

US$4.87
-7.33 (-60.08%)
US$9.88
Fair Value
US$4.87
-7.33 (-60.08%)
50.7% undervalued intrinsic discount
US$9.88
Fair Value
Price US$4.87
AnalystConsensusTarget US$9.88
MathieuMRoy US$30.30
AnalystHighTarget US$14.17

LFMD Community Narratives

·
Fair Value US$9.88 50.7% undervalued intrinsic discount

Expanding Care Domains And Telemedicine Will Unlock New Markets

1users have liked this narrative
1users have commented on this narrative
19users have followed this narrative
Fair Value
·
Fair Value US$30.3 83.9% undervalued intrinsic discount

LifeMD is a diamond in the making

6users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
·
Fair Value US$14.17 65.6% undervalued intrinsic discount

Telemedicine Adoption And Chronic Care Expansion Will Reshape Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
LFMD logo
LifeMD

LifeMD is a diamond in the making

Telehealth is the future of healthcare in america and around the world. Most people don’t want to wait hours in the hospital or even weeks for an appointment.Read more

View narrative
US$30.3
83.9% undervalued intrinsic discount
Fair Value
Profit Margin
14.71%
Future PE
31.41x
Price in 2030
US$43.86
US$8
39.1% undervalued intrinsic discount
Profit Margin
4.07%
Future PE
40.34x
Price in 2028
US$9.4

Trending Discussion

Updated Narratives

LFMD logo

LifeMD is a diamond in the making

Fair Value: US$30.3 83.9% undervalued intrinsic discount
18 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
LFMD logo

LFMD: GLP-1 Virtual Care Expansion Will Support 2026 Revenue Ambitions

Fair Value: US$9.88 50.7% undervalued intrinsic discount
19 users have set this as their fair value
1 users have commented on this narrative
0 users have liked this narrative
LFMD logo

LFMD: Oral GLP 1 Portfolio Will Anchor Future Telehealth Reacceleration

Fair Value: US$14.17 65.6% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
3 Rewards

LifeMD, Inc. Key Details

US$193.3m

Revenue

US$25.5m

Cost of Revenue

US$167.8m

Gross Profit

US$189.1m

Other Expenses

-US$21.3m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.44
86.81%
-11.02%
0%
View Full Analysis

About LFMD

Founded
1994
Employees
350
CEO
Justin Schreiber
WebsiteView website
lifemd.com

LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men’s telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men’s health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.

Recent LFMD News & Updates

Narrative Update Jun 18

LFMD: GLP-1 Virtual Care Expansion Will Support 2026 Revenue Ambitions

Analysts have kept their $9.88 price target on LifeMD broadly unchanged, citing only minor tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in the core valuation view. What’s in the News for LifeMD LifeMD issued earnings guidance for the second quarter, expecting revenue between $47 million and $50 million.
Seeking Alpha Jun 09

LifeMD: A Growing Healthcare Tech Stock, As Q1 Results Confirm Patient Demand

Summary LifeMD offers a compelling growth opportunity, driven by digital healthcare tailwinds and record net subscriber additions in Q1. LFMD trades at a significant valuation discount, with fwd EV/Sales of 0.94x and a Wall St. price target implying 102% upside. Despite strong revenue growth, LFMD faces near-term earnings pressure from elevated marketing spend and negative operating income. LFMD's integrated pharmacy network and cash-rich balance sheet enhance its competitive positioning, but weak ROE and profitability remain key risks. The company has a cash runway of about 8.2 years under current scenario, where debt payments are a major cash impact, despite operating cashflow being positive. Read the full article on Seeking Alpha
Narrative Update Jun 04

LFMD: Oral GLP-1 Virtual Care And Retention Will Shape 2026 Outlook

Analysts have raised their average price target for LifeMD to $9.88, reflecting updated views on lower perceived risk, slightly higher expected revenue growth, and a marginally lower projected profit margin, supported by recent upgrades citing stronger 2026 outlooks, Q4 beats, and patient growth potential tied to the oral GLP-1 portfolio. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price targets, in the US$8 to US$10 range, as reflecting greater confidence in LifeMD's ability to execute on its growth plan and support a higher valuation.

Recent updates

No updates